Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Intergroupe Francophone du Myelome
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03683277CT.gov IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | — | Terminated | — | — | — |
NCT03563053CT.gov Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Intergroupe Francophone du Myelome | P3 | BB · 65 |
| Nexiguran Ziclumeran | Intellia Therapeutics | P3 | B |
| Zeleciment Rostudirsen | Dyne Therapeutics | P3 | B |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | B |
| Fulvestrant | Borstkanker Onderzoek Groep | P2 | CCC |
| Thalidomide | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | P2 | CCC |
| Pomalidomide | Intergroupe Francophone du Myelome | P2 | CCC |
| Alpelisib | Borstkanker Onderzoek Groep | P2 | CCC |
| Cyclophosphamide | Children's Hospital Los Angeles | P2 | CCC |
+7 more in the Hereditary Disease cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Hereditary Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-hereditary-disease-116838
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →